FDA Clearance Could Be A Game Changer For Haemonetics Stock (HAE)

• Haemonetics reported past FDA approval of its PerQseal Elite vascular closure system in the U.S., adding a bioabsorbable, sutureless option for large bore arterial procedures following the Vivasure Medical acquisition.
• The fully bioabsorbable patch and near instant hemostasis data from the ELITE study highlight how PerQseal Elite could influence Haemonetics' mix of higher value interventional products.
• We will look at how Haemonetics' investment narrative is affected by PerQseal Elite's FDA cleared bioabsorbable large bore arterial closure system.

Scan beyond Haemonetics and see how other medtech and device players are positioned by running the hand-picked 30 resilient stocks with low risk scores that filters for resilient balance sheets and solid fundamentals.

Haemonetics Investment Narrative Recap

To own Haemonetics, you need to believe the mix shift toward higher value MedSurg, plasma, and interventional products can offset tariff pressure, leverage, and margin noise from one off items. The core debate is whether current plasma and TEG based hemostasis trends translate into durable earnings quality rather than just headline growth.

The PerQseal Elite approval folds into that question, since it broadens vascular closure within a segment that had already been putting up low double digit growth. If uptake is slower or pricing competitive, the near term impact on margins and cash generation could be modest, while debt of about US$1.2b still keeps balance sheet discipline front of mind.

In this context, the comparison to GE HealthCare is the recent data point that feels most relevant. Both carry a Zacks Rank of #2, with GE HealthCare framed as the stronger value option on P/E, PEG, and P/B, which quietly raises the bar for how investors judge Haemonetics’ current multiple and execution.

For you, that context matters because Haemonetics is already seen as trading at a P/E of 56.5x versus 23.8x for the broader US medical equipment group and is described as expensive on several relative metrics. A richer valuation heightens sensitivity to how quickly PerQseal Elite, NexSys with Persona PLUS, and TEG 6s convert clinical traction into steady earnings and cash flow delivery.

What The PerQseal Elite Story Implies For Haemonetics’ Targets

Haemonetics' narrative projects US$1.6b revenue and US$248.7m earnings by 2029. That lines up with analysts assuming 6.1% yearly revenue growth and an earnings increase of about US$152.4m from US$96.3m today.

Uncover why Haemonetics' fair value indicates a 4% potential upside to its current price that may not last much longer.

Exploring Other Perspectives

Cost pressure is the swing factor that bearish analysts care about most for Haemonetics. Before this PerQseal Elite news, the lowest forecasts still penciled in about US$1.6b of revenue and US$241.8m in earnings by 2029, but with a lower 18.9x P/E. That more cautious story could shift, so compare these views and decide which fits your expectations.

Explore another Haemonetics fair value estimate, including one that suggests it could be worth just $124.50.

Decide For Yourself

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your Haemonetics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• See our latest analysis for Haemonetics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Haemonetics' overall financial health at a glance.

Looking for more investment ideas beyond Haemonetics?

Once you have formed a view on Haemonetics, it can help to cross check that thesis against other opportunities using the Simply Wall St Screener. That way you frame Haemonetics as one option on a wider menu rather than your only choice.

• If you want resilience to be front and center, focus on companies that pair steady balance sheets with measured risk using the 30 resilient stocks with low risk scores.
• For investors hunting for quality at a reasonable price, line Haemonetics up against a broader pool of potentially mispriced opportunities with the 29 high quality undervalued stocks.
• Income focused readers can concentrate on steady cash returns by filtering for yield and staying power through the 5 dividend fortresses.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com